MDCXMedicus Pharma Ltd.vs its industry peers
A metric-by-metric comparison of Medicus Pharma Ltd. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDCXThis | $120M#5 | — | — | — | — | -323.8%#7 | — | — | — | — | -98.4%#2 | — |
| MBIO | — | — | — | — | — | 87.8%#1 | — | -25.5%#2 | — | — | — | — |
| MDCXW | $23M#7 | — | — | — | — | -323.8%#7 | — | — | — | — | — | — |
| MENS | $144M#4 | — | — | — | — | -54.7%#6 | — | — | — | — | — | — |
| MREO | $230M#3 | — | 8.0x#3 | 459.8x#3 | — | -3.2%#4 | -8021.4%#3 | 146.2%#1 | — | — | — | — |
| MRVI | $1.1B#2 | — | 5.6x#2 | 6.2x#1 | -28.3%#1 | 9.7%#3 | -115.9%#1 | -63.9%#4 | -76.4%#1 | — | 148.4%#1 | — |
| MSLE | $105M#6 | — | — | — | — | -20.5%#5 | — | — | — | — | — | — |
| NAMS | $2.4B#1 | — | 3.8x#1 | 106.6x#2 | -50.6%#2 | 16.1%#2 | -1002.9%#2 | -32.1%#3 | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-11-02.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice